Market revenue in 2023 | USD 127.5 million |
Market revenue in 2030 | USD 214.0 million |
Growth rate | 7.7% (CAGR from 2023 to 2030) |
Largest segment | Hereditary non-cancer testing |
Fastest growing segment | Hereditary Cancer Testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 81.25% in 2023. Horizon Databook has segmented the Brazil hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
The advent of novel NIPT solutions and easy availability of hereditary testing products provided by a wide range of distributors is expected to drive Brazilian hereditary testing market. In February 2018, approval of Premaitha’s IONA test by Agência Nacional de Vigilância Sanitária (ANVISA), expanded the scope of prenatal testing in Brazil.
This test can estimate risk of Down’s syndrome or other genetic conditions in fetuses. The company, along with its commercial partners, offered the NIPT to the Brazilian population. DASA Group has offered Natera's noninvasive prenatal diagnostic test in Brazil since August 2013.
In addition, Brazil has around 150 centers offering a wide array of services with Joint Commission International (JCI) accreditation. Increasing medical tourism—owing to lower cost, improving success rate, and statutory level licensing—has increased the demand for PGD in Brazil. Previously, same sex married couples, or single women were not allowed IVF treatments.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into Brazil hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account